Surmodics, Inc. provided earnings guidance for the fiscal year 2024. For the period, the company expects total revenue to be in the range of $117 million to $121 million, representing a decrease of (12)% to (9)% compared to fiscal 2023. Excluding SurVeil DCB license fee revenue, Surmodics expects fiscal 2024 total revenue to range from $113 million to $117 million, representing an increase of 10% to 14% compared to fiscal 2023.

The company expects fiscal 2024 GAAP diluted loss per share to range from $(1.40) to $(1.10).